ArticleFrontiers in oncology2026
Prospective evaluation of dynamic changes in L3 skeletal muscle index and chemotherapy-induced peripheral neuropathy during albumin-bound paclitaxel chemotherapy.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This prospective study aimed to assess the association between dynamic changes in the L3 skeletal muscle index (L3SMI) and chemotherapy-induced peripheral neuropathy (CIPN) in patients receiving albumin-bound paclitaxel (nab-PTX)-based chemotherapy, and examine the impact of sarcopenia and CIPN on survival outcomes. Methods: Patients with malignancies scheduled to receive nab-PTX-based chemotherapy were enrolled. Nutritional status, body composition assessed by bioelectrical impedance analysis, and L3SMI measured using computed tomography were assessed at baseline and after three chemotherapy cycles. CIPN was assessed using the Patient Neurotoxicity Questionnaire after the first and third cycles. Patients were stratified according to baseline sarcopenia status and CIPN severity (high-grade, CIPN-H ≥ grade C; low-grade, CIPN-L < grade C). Results: Among the 152 enrolled patients, 56 completed all assessments. After three chemotherapy cycles, L3SMI decreased significantly from 32.77 to 31.93 cm²/m² ( Conclusion: Progressive loss of skeletal muscle-related body composition parameters during nab-PTX-based chemotherapy was accompanied by increased CIPN severity. CIPN-H was associated with poorer OS, but this association should be interpreted cautiously because of potential confounding by disease severity and treatment intensity. These findings support the importance of assessing body composition and implementing interventions targeting sarcopenia to reduce the risk of CIPN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.